# IBIO earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/IBIO) · [Earnings tab](https://www.lopjlb.com/stock/IBIO?tab=earnings) Updated: 2026-08-31T01:10:45 Quarters analyzed: 7 ## Cross-quarter narrative Across the series of earnings CallCards, iBio’s strategic focus shifted from a CDMO‑centric model toward building a proprietary pipeline anchored by its FastPharming platform. Early 2021 highlighted a broad set of vaccine and therapeutic candidates (iBio‑201, iBio‑200, ACE2‑Fc, iBio‑100, iBio‑400) and the nascent FastPharming technology. By late 2021 the company added oncology assets (RTX‑003/iBio‑101) and emphasized platform scaling while discontinuing the ACE2‑Fc project. In 2022 the narrative turned to rapid progress on a nucleocapsid‑based COVID‑19 vaccine (IBIO‑202) and six new oncology programs, alongside the RubrYc AI acquisition. However, cash‑runway concerns grew, with auditors flagging a going‑concern risk and the cash balance projected to last only through September 2023. Regulatory uncertainty persisted, culminating in the cancellation of the IBIO‑202 IND after negative animal data. Meanwhile, FastPharming delivered antibody data and continued scaling, but integration and adoption risks remained. The company’s financial posture deteriorated, prompting discussions of reverse splits, sale‑lease‑backs, and asset sales. Overall, iBio moved deeper into proprietary product development, yet faced mounting financial, regulatory, and technology‑execution challenges. ## Latest CallCard · Q4 iBio announced a transformative RubrYc acquisition, pushed IBIO-101 IND filing to H1 2024, halted IBIO-202 vaccine after negative animal data, and warned of a going‑concern situation while seeking cash‑runway extensions. **Guidance:** vague — Management said it is premature to provide additional color on cash‑runway extension options and gave no new quantitative guidance. **Tone:** mgmt 0.5 · Q&A pressure 0.6 · divergence 0.2 Management described the RubrYc deal as transformative and expressed confidence in extending the cash runway despite challenges. ### Demand visibility Limited visibility on cash runway and IND timelines Management is evaluating asset sales, partnerships, cost reductions and non‑dilutive financing but provided no firm timeline for cash‑runway extension or IND filing beyond H1 2024. ### Margins / costs R&D and G&A expenses rose sharply R&D increased by $7.7 M and G&A by $12.1 M year‑over‑year, reflecting investment in the AI platform and pipeline expansion. ### Capital allocation Focus on acquisition, pipeline and cash‑runway options Upfront payment of ~ $1 M in stock for RubrYc, potential $5 M in milestone payments, and ongoing evaluation of asset sales, partnerships and financing to extend cash runway. ### Milestones - **RubrYc acquisition** [delivered]: Acquisition completed, adding AI drug‑discovery platform and four new pipeline assets. - **IBIO-101 IND filing** [on_track]: Pre‑IND submitted; IND filing expected in the first half of calendar 2024. - **IBIO-202 vaccine program** [delayed]: Preclinical data showed no protective effect; IND submission cancelled. - **Target 6 program** [on_track]: Advanced to late discovery; preparing in‑vivo proof‑of‑concept studies. - **PD‑1 agonist program** [on_track]: In late discovery stage; in‑vivo proof‑of‑concept studies being planned. ### Fears / risks - **Cash runway**: Auditors expressed substantial doubt about the company’s ability to continue as a going concern. - **Regulatory risk**: IBIO-202 vaccine failed to demonstrate efficacy in preclinical challenge studies, halting IND plans. - **Technology integration**: Integrating RubrYc’s AI platform with existing iBio platforms may encounter execution challenges. - **Funding risk**: Reliance on asset sales, partnerships or dilutive financing creates uncertainty about raising needed capital. - **Clinical failure**: Early‑stage programs could fail to progress to clinic despite AI‑driven discovery claims. - **Market competition**: Competing COVID‑19 vaccines and established immuno‑oncology players may limit commercial upside. ### Key quotes > “We believe the RubrYc transaction we announced last week is transformative for iBio.” > “The company and its auditors have concluded their substantial doubt about the company's ability to continue as a going concern.” ## Quarter one-liners - **2022 Q4:** iBio announced a transformative RubrYc acquisition, pushed IBIO-101 IND filing to H1 2024, halted IBIO-202 vaccine after negative animal data, and warned of a going‑concern situation while seeking cash‑runway extensions. - **2022 Q3:** iBio reported FDA feedback on its COVID vaccine candidate, IND plans for IBIO-202, completed lead optimization of IBIO-101, highlighted FastPharming data, raised inventory for upcoming trials, and discussed a reverse split and potential sale‑leaseback. - **2022 Q2:** iBio reports rapid progress on its nucleocapsid‑based COVID vaccine and six new oncology assets, but notes weak Q2 revenue, cash runway to Sep 2023 and aims to file an IND for IBIO‑202 by year‑end. - **2021 Q4:** iBio expanded its oncology pipeline with RTX-003 licensing, advanced a COVID vaccine pre‑IND, highlighted FastPharming benefits, disclosed a discontinued ACE2 project and factored San Diego facility costs into cash burn. - **2021 Q3:** — - **2021 Q2:** — - **2021 Q1:** iBio reports Q1 FY21 with $410k revenue, $83.5M cash; advances COVID-19 vaccine iBio-201 toward clinic, selects lead candidate, initiates toxicology, FDA talks; transforms from CDMO to proprietary pipeline with FastPharming platform. ## Theme arcs - **Proprietary pipeline development** (improving): Expanded from initial vaccine candidates to multiple oncology assets and AI‑driven discovery. - **FastPharming platform adoption** (improving): Scaled platform, delivered antibody data, but faces adoption and integration risk. - **COVID‑19 vaccine program** (deteriorating): Initial progress on iBio‑201/202 halted after preclinical failure and IND cancellation. - **Oncology pipeline expansion** (improving): Added RTX‑003/iBio‑101, six new oncology assets, Target 6 and PD‑1 agonist programs. - **Financial health and cash runway** (deteriorating): Cash projected to run out by Sep 2023, auditors issued going‑concern warning, exploring financing options. - **Regulatory risk** (stable): Ongoing uncertainty around FDA IND acceptances and vaccine approvals. - **Partnership and AI integration** (new): RubrYc acquisition completed, creating AI‑driven antibody discovery capability. - **Supply‑chain and manufacturing risk** (new): Supply‑chain constraints noted in Q3 2022 could delay manufacturing timelines. ## Guidance path 2021 Q1:vague → 2021 Q2:vague → 2021 Q3:vague → 2021 Q4:maintained → 2022 Q2:maintained → 2022 Q3:maintained → 2022 Q4:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/IBIO`